Strategies, development, and pitfalls of therapeutic options for Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 28, Issue 2, 2012, Pages 241-281

  Haas, Christopher ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; amyloid ; drug therapy; humans; investigational drugs; pathophysiology; tau

Indexed keywords

AMYLOID BETA PROTEIN; AVAGACESTAT; BEGACESTAT; BETA SECRETASE; BETA SECRETASE INHIBITOR; BRYOSTATIN 1; CHF 5074; CTS 21166; DONEPEZIL; E2012; ETRETIN; GALANTAMINE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; LY 2811376; MEMANTINE; MK 0752; NIC5 15; PHENSERINE; RIVASTIGMINE; RO 5313534; RO5313534; SEMAGACESTAT; SIMVASTATIN; TACRINE; TALSACLIDINE; TAMIBAROTENE; TARENFLURBIL; TAU PROTEIN; TC 5619; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; LACRIMATION; LIVER TOXICITY; MIOSIS; NEUROPROTECTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SALIVATION; SIDE EFFECT; URINE INCONTINENCE; VOMITING;

EID: 84856990182     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110986     Document Type: Review

References (422)

1. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75, 333-366. (Pubitemid 44118036)
2. Gregersen N (2006) Protein misfolding disorders: Patho-genesis and intervention. J Inherit Metab Dis 29, 456-470. (Pubitemid 43880651)
3. Haas C (2008) Tangled up in tau. In Protein Misfolding In Biology And Disease - "Tangled up in Tau", Outeiro TF, ed. Transworld Research Netowrk, Kerala, pp. 91-126.
4. Rochet JC (2006) Errors in translation cause selective neu-rodegeneration. ACS Chem Biol 1, 562-566.
5. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde".Clin Anat 8, 429-431.
6. Citron M Alzheimer's disease: Strategies for disease modification. Nat Rev Drug Discov 9, 387-398.
7. Delacourte A, Defossez A (1986) Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J Neurol Sci 76, 173-186. (Pubitemid 17176077)
8. Glenner GG, Wong CW (1984) Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890. (Pubitemid 14104991)
9. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261, 6084-6089. (Pubitemid 17207447)
10. Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83, 4044-4048. (Pubitemid 16062419)
11. Wong CW, Quaranta V, GlennerGG (1985) Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are anti-genically related. Proc Natl Acad Sci U S A 82, 8729-8732. (Pubitemid 16101117)
12. Ihara Y, Nukina N, Miura R, Ogawara M (1986) Phospho-rylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem 99, 1807-1810.
13. Frisardi V, Panza F, Farooqui AA (2011) Late-life depression and Alzheimer's disease: The glutamatergic system inside of this mirror relationship. Brain Res Rev 67, 344-355.
14. Potter GG, Steffens DC (2007) Contribution of depression to cognitive impairment and dementia in older adults. Neurologist 13, 105-117. (Pubitemid 46743077)
15. de Beaurepaire R (2002) Questions raised by the cytokine hypothesis of depression. Brain Behav Immun 16, 610-617. (Pubitemid 35333742)
16. Alexopoulos GS, Meyers BS, Young RC, Mattis S, Kakuma T (1993) The course of geriatric depression with "reversible dementia": A controlled study. Am J Psychiatry 150, 1693-1699. (Pubitemid 23325953)
17. Butters MA, Young JB, Lopez O, Aizenstein HJ, Mulsant BH, Reynolds CF 3rd, DeKosky ST, Becker JT (2008) Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci 10, 345-357.
18. Heneka MT, O'Banion MK, Terwel D, KummerMP (2010) Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 117, 919-947.
19. Panza F, Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Vendemiale G, Capurso A, Imbimbo BP (2009) Disease-modifying approach to the treatment of Alzheimer's disease: From alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging 26, 537-555.
20. Alzheimer's Association, Alzheimer's Fact Sheet, http://www.alz.org/ document/2011 Fact Figures Fact sheet.pdf, Accessed April 25, 2011.
21. Hardy JA, Higgins GA (1992) Alzheimer's disease: The amyloid cascade hypothesis. Science 256, 184-185.
22. van Marum RJ (2008) Current and future therapy in Alzheimer's disease. Fundam Clin Pharmacol 22, 265-274. (Pubitemid 351712889)
23. Heber S, Herms J, Gajic V, Hainfellner J, Aguzzi A, Rulicke T, von Kretzschmar H, von Koch C, Sisodia S, Tremml P, Lipp HP, Wolfer DP, Muller U (2000) Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. J Neurosci 20, 7951-7963.
24. Turner PR, O'Connor K, Tate WP, Abraham WC (2003) Rolesofamyloid precursor protein and its fragmentsinregu-lating neural activity, plasticity and memory.Prog Neurobiol 70, 1-32. (Pubitemid 36966639)
25. Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisoda SS, Chen HY, Van der Ploeg LH (1995) beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81, 525-531.
26. Kinbara K, Kitagaki H, Kinouchi T, Okano M, Sorimachi H, Ishiura S, Suzuki K (1994) Processing and secretion of Alzheimer's disease amyloid precursor protein. Tohoku J Exp Med 174, 209-216.
27. Kimberly WT, Zheng JB, Guenette SY, Selkoe DJ (2001) The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem 276, 40288-40292.
28. Kinoshita A, Whelan CM, Berezovska O, Hyman BT (2002) The gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces apoptosis via Tip60 in H4 cells. J Biol Chem 277, 28530-28536. (Pubitemid 41079279)
29. Sastre M, Dewachter I, Landreth GE, Willson TM, Klockgether T, van Leuven F, Heneka MT (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 23, 9796-9804. (Pubitemid 37371592)
30. Velliquette RA, O'Connor T, Vassar R (2005) Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: Possible early eventsinAlzheimer's disease pathogenesis. J Neurosci 25, 10874-10883. (Pubitemid 41692617)
31. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, Beyreuther K, Masters CL (1988) A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: Prevalence in aged brains determined by immuno-cytochemistry compared with conventional neuropathologic techniques. Neurology 38, 1688-1693. (Pubitemid 18265030)
32. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR (2000) "Preclinical" AD revisited: Neuropathology of cognitively normal older adults. Neurology 55, 370-376. (Pubitemid 30654797)
33. Ittner LM, Gotz J (2011) Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12, 65-72.
34. Duyckaerts C, Potier MC, Delatour B (2008) Alzheimer disease models and human neuropathology: Similarities and differences. Acta Neuropathol 115, 5-38. (Pubitemid 50005258)
35. Hardy J (1999) The shorter amyloid cascade hypothesis. Neurobiol Aging 20, 85; discussion 87. (Pubitemid 29352368)
36. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12, 383-388.
37. Small SA, DuffK (2008) Linking Abeta and tau inlate-onset Alzheimer'sdisease:A dual pathway hypothesis. Neuron60, 534-542.
38. Gendron TF, Petrucelli L (2009) The role of tau in neurode-generation. Mol Neurodegener 4, 13.
39. Braak H, Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16, 271-278; discussion 278-284.
40. Chen J, Kanai Y, Cowan NJ, Hirokawa N (1992) Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature 360, 674-677. (Pubitemid 23007681)
41. Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP (2001) Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114, 1179-1187. (Pubitemid 32288531)
42. Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T, Sato-Yoshitake R, Takei Y, Noda T, Hirokawa N (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature 369, 488-491. (Pubitemid 24210568)
43. Ikegami S, Harada A, Hirokawa N (2000) Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci Lett 279, 129-132. (Pubitemid 30069810)
44. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P (1998) Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705.
45. Spillantini MG, Bird TD, Ghetti B (1998) Frontotemporal dementia and Parkinsonism linked to chromosome 17: A new group of tauopathies. Brain Pathol 8, 387-402. (Pubitemid 28186074)
46. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 95, 7737-7741. (Pubitemid 28293323)
47. Goedert M, Crowther RA, Spillantini MG (1998) Tau mutations cause frontotemporal dementias. Neuron 21, 955-958. (Pubitemid 29018067)
48. Jeganathan S, von Bergen M, Brutlach H, Steinhoff HJ, Mandelkow E (2006) Global hairpin folding of tau in solution. Biochemistry 45, 2283-2293. (Pubitemid 43271328)
49. Mendieta J, Fuertes MA, Kunjishapatham R, Santa-Maria I, Moreno FJ, Alonso C, Gago F, Munoz V, Avila J, Hernandez F (2005) Phosphorylation modulates the alpha-helical structure and polymerization of a peptide from the third tau microtubule-binding repeat. Biochim Biophys Acta 1721, 16-26. (Pubitemid 40093508)
50. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A 91, 5562-5566. (Pubitemid 24174368)
51. Alonso AD, Grundke-Iqbal I, Barra HS, Iqbal K (1997) Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: Sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA 94, 298-303.
52. Kaneko K, Peretz D, Pan KM, Blochberger TC, Wille H, Gabizon R, Griffith OH, Cohen FE, Baldwin MA, Prusiner SB (1995) Prion protein (PrP) synthetic peptides induce cellular PrP to acquire properties of the scrapie isoform. Proc Natl Acad Sci USA 92, 11160-11164.
53. Castellani RJ, Lee HG, Zhu X, Perry G, Smith MA (2008) Alzheimer disease pathology as a host response. J Neu-ropathol Exp Neurol 67, 523-531. (Pubitemid 351787079)
54. Castellani RJ, Smith MA (2011) Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. J Pathol 224, 147-152.
55. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Sied-lak SL, Tabaton M, Perry G (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70, 2212-2215. (Pubitemid 28207848)
56. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, Wiggert B, Petersen RB, Perry G (1994) Heme oxygenase-1 isassociated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 145, 42-47. (Pubitemid 24217481)
57. Rogers J, Morrison JH (1985) Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci 5, 2801-2808. (Pubitemid 16232369)
58. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L (1988) Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38, 1682-1687. (Pubitemid 18265029)
59. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly.Arch Neurol 65, 1509-1517.
60. Peskind ER, Li G, Shofer. J, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko DR (2006) Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 63, 936-939. (Pubitemid 44036292)
61. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
62. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive statusinAlzheimer's disease.Neurology60, 1495-1500. (Pubitemid 36559525)
63. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
64. Arriagada PV, Marzloff K, Hyman BT (1992) Distributionof Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern inAlzheimer's disease. Neurology 42, 1681-1688.
65. Gentleman SM, Graham DI, Roberts GW (1993) Molecular pathology of head trauma: Altered beta APP metabolism and the aetiology of Alzheimer's disease. Prog Brain Res 96, 237-246. (Pubitemid 23185296)
66. Blumbergs PC, Scott G, Manavis J, Wainwright H, Simpson DA, McLean AJ (1995) Topography of axonal injury as defined by amyloid precursor protein and the sector scoring method in mild and severe closed head injury. J Neuro-trauma 12, 565-572.
67. Brugg B, Dubreuil YL, Huber G, Wollman EE, Delhaye-Bouchaud N, Mariani J (1995) Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc Natl Acad Sci U S A 92, 3032-3035.
68. Frederikse PH, Garland D, Zigler JS Jr, Piatigorsky J (1996) Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J Biol Chem271, 10169-10174. (Pubitemid 26131580)
69. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA et al (1994) Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc Natl Acad Sci USA91, 7787-7791. (Pubitemid 24238270)
70. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P et al (1995) Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med 1, 693-699.
71. Panegyres PK (1998) The effects of excitotoxicity on the expression of the amyloid precursor protein gene in the brain and its modulation by neuroprotective agents. J Neural Transm 105, 463-478. (Pubitemid 28365029)
72. Lee HG, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA (2007) Amyloid-beta in Alzheimer disease: The null versus the alternate hypotheses. J Pharmacol Exp Ther 321, 823-829. (Pubitemid 46762675)
73. Higgins GA, Oyler GA, Neve RL, Chen KS, Gage FH (1990) Altered levels of amyloid protein precursor transcripts in the basal forebrain of behaviorally impaired aged rats. Proc Natl Acad Sci USA 87, 3032-3036.
74. Nordstedt C, Gandy SE, Alafuzoff I, Caporaso GL, Iverfeldt K, Grebb JA, Winblad B, Greengard P (1991) Alzheimer beta/A4 amyloid precursor protein in human brain: Aging-associated increases in holoprotein and in a proteolytic fragment. Proc Natl Acad Sci USA 88, 8910-8914. (Pubitemid 21915539)
75. van Gool WA, Schenk DB, Bolhuis PA (1994) Concentrations of amyloid-beta protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease. Neurosci Lett 172, 122-124.
76. Whitson JS, Glabe CG, Shintani E, Abcar A, Cotman CW (1990) Beta-amyloid protein promotes neuritic branching in hippocampal cultures. Neurosci Lett 110, 319-324. (Pubitemid 20070713)
77. Whitson JS, Selkoe DJ, Cotman CW (1989) Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science 243, 1488-1490. (Pubitemid 19087137)
78. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Bal-raj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60, 759-767. (Pubitemid 32678256)
79. Andorn AC, Kalaria RN (2000) Factors affecting pro- and anti-oxidant properties of fragments of the ß-Protein Precursor (ßPP): Implication for Alzheimer's disease. J Alzheimers Dis 2, 69-78.
80. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang X, Farrag YW, Perry G, Bush AI (2000) Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 275, 19439-19442. (Pubitemid 30441532)
81. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI (1998) Dramatic aggregation of Alzheimer Abeta by Cu (II) is induced by conditions representing physiological acidosis. J Biol Chem 273, 12817-12826. (Pubitemid 28246837)
82. Bishop GM, Robinson SR (2003) Deposits of fibrillar A beta do not cause neuronal loss or ferritin expression in adult rat brain. J Neural Transm 110, 381-400. (Pubitemid 36428387)
83. Kontush A, Berndt C, Weber W, Akopyan V, Arlt S, Schip-pling S, Beisiegel U (2001) Amyloid-beta is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 30, 119-128. (Pubitemid 32008095)
84. Hayashi T, Shishido N, Nakayama K, Nunomura A, Smith MA, Perry G, Nakamura M (2007) Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic Biol Med 43, 1552-1559. (Pubitemid 47615399)
85. Nakamura M, Shishido N, Nunomura A, Smith MA, Perry G, Hayashi Y, Nakayama K, Hayashi T (2007) Three his-tidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry 46, 12737-12743. (Pubitemid 350064223)
86. Bush AI, Tanzi RE (2008) Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5, 421-432. (Pubitemid 351952485)
87. Lee HG, Zhu X, Nunomura A, Perry G, Smith MA (2006) Amyloid beta: The alternate hypothesis. Curr Alzheimer Res 3, 75-80.
88. Giulivi C, Cadenas E (1993) The reaction of ascorbic acid with different heme iron redox states of myoglobin. Antiox-idant and prooxidant aspects. FEBS Lett 332, 287-290. (Pubitemid 23305342)
89. Hisanaga K, Sagar SM, Sharp FR (1992) Ascorbate neuro-toxicity in cortical cell culture. Ann Neurol 31, 562-565.
90. Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA (2006) Neuropathology of Alzheimer disease: Pathognomonic but not pathogenic. Acta Neuropathol 111, 503-509. (Pubitemid 43778954)
91. Nunomura A, Chiba S, Lippa CF, Cras P, Kalaria RN, Takeda A, Honda K, Smith MA, PerryG (2004) Neuronal RNAoxi-dationisaprominent featureoffamilial Alzheimer's disease. Neurobiol Dis 17, 108-113. (Pubitemid 39209318)
92. Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, Smith MA (1999) Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci 893, 362-364. (Pubitemid 30038105)
93. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA (2000) Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 59, 1011-1017.
94. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, Smith MA (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19, 1959-1964. (Pubitemid 29133374)
95. Guo Q, Sopher BL, Furukawa K, Pham DG, Robinson N, Martin GM, Mattson MP (1997) Alzheimer's prese-nilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: Involvement of calcium and oxyradicals. J Neurosci 17, 4212-4222. (Pubitemid 27220612)
96. Leutner S, Czech C, Schindowski K, Touchet N, Eckert A, Muller WE (2000) Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations. Neurosci Lett 292, 87-90.
97. Marques CA, Keil U, Bonert A, Steiner B, Haass C, Muller WE, Eckert A (2003) Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: Oxidative stress, caspases, and the JNK pathway. J Biol Chem 278, 28294-28302. (Pubitemid 36900031)
98. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, Guidi I, Blankenstein MA, Bresolin N, Scarpini E (2006) Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol 63, 538-543.
99. Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoo-nenboom NS, Hack CE, Blankenstein MA, Jonker C (2009) Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging 30, 1885-1889.
100. Tarkowski E, Andreasen N, Tarkowski A, Blennow K (2003) Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 74, 1200-1205.
101. Lavados M, Guillon M, Mujica MC, Rojo LE, Fuentes P, Maccioni RB (2008) Mild cognitive impairment and Alzheimer patients display different levels of redox-active CSF iron. J Alzheimers Dis 13, 225-232. (Pubitemid 352038527)
102. Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. Science 250, 279-282.
103. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith MA (2001) Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30, 447-450. (Pubitemid 32155543)
104. Castellani RJ, Nunomura A, Lee HG, Perry G, Smith MA (2008) Phosphorylated tau: Toxic, protective, or none of the above. J Alzheimers Dis 14, 377-383.
105. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41, 17-24. (Pubitemid 27057088)
106. Kril JJ, Patel S, Harding AJ, Halliday GM (2002) Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neu-ropathol 103, 370-376. (Pubitemid 36097032)
107. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307, 1282-1288. (Pubitemid 40299973)
108. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337-351. (Pubitemid 46161268)
109. Kraemer BC, Burgess JK, Chen JH, Thomas JH, Schellenberg GD (2006) Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. Hum Mol Genet 15, 1483-1496.
110. Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38, 3549-3558.
111. Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mer-cken M, Bruynseels K, Lasrado R, Vandezande K, Laenen I, Boon T, Van Lint J, Vandenheede J, Moechars D, Loos R, Van Leuven F (2000) Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem 275, 41340-41349. (Pubitemid 32054968)
112. Ekinci FJ, SheaTB (2000) Beta-Amyloid-Induced tau phos-phorylation does not correlate with degeneration in cultured neurons. J Alzheimers Dis 2, 7-15. (Pubitemid 30353513)
113. Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S, Szweda LI, Kaminski MA, Avila J, Price DL, Cleveland DW, Sayre LM, Perry G (2002) High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynone-nal. J Biol Chem 277, 4644-4648. (Pubitemid 34968493)
114. Zhu X, Rottkamp CA, Boux H, Takeda A, Perry G, Smith MA (2000) Activation of p38 kinase links tau phospho-rylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol 59, 880-888.
115. Ikegami K, Heier RL, Taruishi M, Takagi H, Mukai M, Shimma S, Taira S, Hatanaka K, Morone N, Yao I, Campbell PK, Yuasa S, Janke C, Macgregor GR, Setou M (2007) Loss of alpha-tubulin polyglutamylation in ROSA22 mice is associated with abnormal targeting of KIF1A and modulated synaptic function. Proc Natl Acad Sci USA 104, 3213-3218. (Pubitemid 46364139)
116. Rogowski K, van Dijk J, Magiera MM, Bosc C, Deloulme JC, Bosson A, Peris L, Gold ND, Lacroix B, Grau MB, Bec N, Larroque C, Desagher S, Holzer M, Andrieux A, Moutin MJ, Janke C (2010) A family of protein-deglutamylating enzymes associated with neurodegeneration. Cell 143, 564-578.
117. Boucher D, Larcher JC, Gros F, Denoulet P (1994) Polyglutamylation of tubulin as a progressive regulator of in vitro interactions between the microtubule-associated protein Tau and tubulin. Biochemistry 33, 12471-12477. (Pubitemid 24340453)
118. Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ (2008) Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 62, 199-207. (Pubitemid 351635842)
119. Smith MA (1998) Alzheimer disease. Int Rev Neurobiol 42, 1-54. (Pubitemid 128788937)
120. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215, 1237-1239. (Pubitemid 12106486)
121. Whitehouse PJ, Struble RG, Clark AW, Price DL (1982) Alzheimer disease: Plaques, tangles, and the basal forebrain. Ann Neurol 12, 494.
122. Farlow MR, Evans RM (1998) Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology 51, S36-S44; discussion S65-S37. (Pubitemid 28345340)
123. Neugroschl J, Sano M (2010) Current treatment and recent clinical research in Alzheimer's disease. Mt Sinai J Med 77, 3-16.
124. Giacobini E (2000) Cholinesterase inhibitors stabilize Alzheimer's disease. Ann N Y Acad Sci 920, 321-327. (Pubitemid 32056588)
125. Giacobini E, Mori F, Lai CC (1996) The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex. Ann N Y Acad Sci 777, 393-398. (Pubitemid 26149220)
126. Mori F, Lai CC, Fusi F, Giacobini E (1995) Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 6, 633-636.
127. Bailey JA, Ray B, Greig NH, Lahiri DK (2011) Rivastigmine lowers abeta and increases sAPPa levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PloS one 6, e21954.
128. Bailey JA, Lahiri DK (2010) A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem 112, 843-853.
129. Camps P, Formosa X, Galdeano C, Munoz-Torrero D, Ramirez L, Gomez E, Isambert N, Lavilla R, Badia A, Clos MV, Bartolini M, Mancini F, Andrisano V, Arce MP, Rodriguez-Franco MI, Huertas O, Dafni T, Luque FJ (2009) Pyrano[3, 2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem 52, 5365-5379.
130. Lau A, Tymianski M (2010) Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 460, 525-542.
131. Wang Y, Qin ZH (2010) Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis 15, 1382-1402.
132. Aderinwale OG, Ernst HW, Mousa SA (2010) Current therapies and new strategies for the management of Alzheimer's disease. Am J Alzheimers Dis Other Demen 25, 414-424.
133. Grossberg GT, Edwards KR, Zhao Q (2006) Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. J Clin Pharmacol 46, 17S-26S. (Pubitemid 43882808)
134. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291, 317-324. (Pubitemid 38101604)
135. Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R (2006) Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9, 1520-1525. (Pubitemid 44862660)
136. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314, 664-666. (Pubitemid 44646394)
137. Hu X, He W, Diaconu C, Tang X, Kidd GJ, Macklin WB, Trapp BD, Yan R (2008) Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J 22, 2970-2980.
138. Ghosh AK, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain KA, Hong L, Loy JA, Nguyen C, Koelsch G, Ermolieff J, Tang J (2001) Structure-based design: Potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem 44, 2865-2868. (Pubitemid 32879115)
139. Ghosh AK, Kumaragurubaran N, Hong L, Koelsh G, Tang J (2008) Memapsin 2 (beta-secretase) inhibitors: Drug development. Curr Alzheimer Res 5, 121-131. (Pubitemid 351536337)
140. Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni S, Xu X, Miller HB, Reddy DS, Weerasena V, Turner R, Chang W, Koelsch G, Tang J (2008) Potent memapsin 2 (beta-secretase) inhibitors: Design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. Bioorg Med Chem Lett 18, 1031-1036. (Pubitemid 351179350)
141. Turner RT, 3rd, Hong L, Koelsch G, Ghosh AK, Tang J (2005) Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase). Biochemistry 44, 105-112. (Pubitemid 40095711)
142. Strobel G, News: Keystone Drug News. - CoMentis BACE Inhibitor Debuts, http://alzforum.org/new/detail. asp?id=1790, April 8, 2008, Accessed April 28, 2011.
143. Gardner E (2008) Purdue-designed Alzheimer's treatment completes first phase of testing, http://news. uns.purdue.edu/x/2008a/080117GhoshAlzheimers. html, January 17, 2008, Accessed September 13, 2011.
144. CoMentis, CoMentis announces proof-of-activity data from its Phase I study of disease-modifying Alzheimer's disease therapy, http://www.marketwire. com/press-release/comentis-announces-proof-activity-data-from-its-phase-i-study- disease-modifying-alzheimers-808028.htm, January 07, 2008, Accessed September 13, 2011.
145. Ikari H, Spangler EL, Greig NH, Pei XF, Brossi A, Speer D, Patel N, Ingram DK (1995) Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. Neuroreport 6, 481-484.
146. Araujo JA, Greig NH, Ingram DK, Sandin J, de Rivera C, Milgram NW (2011) Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs. J Alzheimers Dis 26, 143-155.
147. Drugs in Clinical Trials - Phenserine, http://www.alzforum.org/dis/tre/ drc/detail.asp?id=56, December 19, 2008, Accessed August 21, 2011.
148. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, Ge YW, Lahiri DK, Greig NH (2001) Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A 98, 7605-7610. (Pubitemid 32567995)
149. Lahiri DK, Chen D, Maloney B, Holloway HW, Yu QS, Utsuki T, Giordano T, Sambamurti K, Greig NH (2007) The experimental Alzheimer's disease drug posiphen [ (+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 320, 386-396. (Pubitemid 46025753)
150. QRPharma, Press Release: QR. Pharma's Posiphen was shown in a clinical mechanism of action study to enter the brain and to inhibit amyloid precursor protein, http://.qrpharma.com/pr-posiphen.html, July 14, 2010, Accessed August 19, 2011.
151. QRPharma, QR. Pharma to present poster at International Conferences on Alzheimer's Disease, http://www. qrpharma.com/pr-international-alzheimers.html, July 12, 2011, Accessed August 21, 2011.
152. Chang WP, Downs D, Huang XP, Da H, Fung KM, Tang J (2007) Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization. FASEB J 21, 3184-3196. (Pubitemid 47565537)
153. Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, Peng K, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W, Wu Y, Tessier-Lavigne M, Watts RJ (2011) A Therapeutic antibody targeting BACE1 Inhibits amyloid-{beta} production in vivo. Sci Transl Med 3, 84ra43.
154. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA (2003) The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci 23, 5531-5535. (Pubitemid 36807828)
155. Best JD, Jay MT, Otu F, Ma. J, Nadin A, Ellis S, Lewis HD, Pattison C, Reilly M, Harrison T, Shearman MS, Williamson TL, Atack JR (2005) Quantitative measurement of changes in amyloid-beta (40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[ (2S)-2- (3, 5-difluorophenyl)-2-hydroxyethanoyl]-N1-[ (7S)-5-methyl-6-ox o-6, 7-dihydro-5H-dibenzo[b, d]azepin-7-yl]-L-alaninamide]. J Pharmacol Exp Ther 313, 902-908. (Pubitemid 40604194)
156. Elvang AB, Volbracht C, Pedersen LO, Jensen KG, Karls-son JJ, Larsen SA, Mork A, Stensbol TB, Bastlund JF (2009) Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J Neurochem 110, 1377-1387.
157. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM (2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12, 856-861. (Pubitemid 44050079)
158. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Brown-ing KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66, 48-54.
159. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ (2008) Phase 2 safety trial targeting amyloid beta production withagamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65, 1031-1038.
160. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC (2005) Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 28, 126-132. (Pubitemid 40923411)
161. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC (2007) Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 30, 317-325. (Pubitemid 350307310)
162. Siemers ER, Quinn JF, Kaye. J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knop-man DS, Satterwhite J, Gonzales C, Dean RA, May PC (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602-604. (Pubitemid 43739900)
163. McKee S, Lilly hit by spectaculat failure of Phase III Alzhimer's candidate, http://www.pharmatimes.com/Article/10-08-18/Lilly hit by spectacular failure of Phase III Alzheimer s candidate.aspx, August 18, 2010, Accessed April 25, 2011.
164. Bittner T, Fuhrmann M, Burgold S, Jung CK, Volbracht C, Steiner H, Mitteregger G, Kretzschmar HA, Haass C, Herms J (2009) Gamma-secretase inhibition reduces spine density in vivoviaanamyloid precursor protein-dependent pathway. J Neurosci 29, 10405-10409.
165. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ (2004) Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82, 341-358. (Pubitemid 39485346)
166. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM (2004) Chronic treatment with the gamma-secretase inhibitor LY-411, 575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279, 12876-12882. (Pubitemid 38445862)
167. Chiaramonte R, Calzavara E, Balordi F, Sabbadini M, Capello D, Gaidano G, Serra A, Comi P, Sherbet GV (2003) Differential regulation of Notch signal transduction in leukaemia and lymphoma cells in culture. J Cell Biochem 88, 569-577. (Pubitemid 36158276)
168. Drugs in Clinical Trials: BMS-708163, http://www. alzforum.org/drg/drc/ detail.asp?id=124, December 21, 2009, Accessed April 25, 2011.
169. Golde TE, Petrucelli L, Lewis J (2010) Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol 223, 252-266.
170. Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS (2009) Begacestat (GSI-953): A novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 331, 598-608.
171. Mayer SC, Kreft AF, Harrison B, Abou-Gharbia M, Antane M, Aschmies S, Atchison K, Chlenov M, Cole DC, Comery T, Diamantidis G, Ellingboe J, Fan K, Galante R, Gonzales C, Ho DM, Hoke ME, Hu Y, Huryn D, Jain U, Jin M, Kremer K, Kubrak D, Lin M, Lu P, Magolda R, Martone R, Moore W, Oganesian A, Pangalos MN, Porte A, Reinhart P, Resnick L, Riddell DR, Sonnenberg-Reines J, Stock JR, Sun SC, Wagner E, Wang T, Woller K, Xu Z, Zaleska MM, Zeldis J, Zhang M, Zhou H, Jacobsen JS (2008) Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. J Med Chem 51, 7348-7351.
172. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 112, 440-449. (Pubitemid 38063773)
173. Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, Nicolle MM (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 8, 54.
174. Leuchtenberger S, Beher D, Weggen S (2006) Selective modulation of Abeta42 production in Alzheimer's disease: Non-steroidal anti-inflammatory drugs and beyond. Curr Pharm Des 12, 4337-4355. (Pubitemid 44718293)
175. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216. (Pubitemid 33051236)
176. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH (2003) Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 278, 31831-31837. (Pubitemid 37048365)
177. Aisen PS (2008) Tarenflurbil: A shot on goal. Lancet Neurol 7, 468-469.
178. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 302, 2557-2564.
179. Marder K (2010) Tarenflurbil in patients with mild Alzheimer's disease. Curr Neurol Neurosci Rep 10, 336-337.
180. Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, Mather G, Laughlin M, Zavitz KH, Swabb E, Golde TE, Murphy MP, Koo EH (2007) Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 21, 292-299. (Pubitemid 350307433)
181. Pollack A, Myriad Genetics stops work on Alzheimer's drug, New York Times, http://www.nytimes.com/2008/07/01/business/01gene.html, July1, 2008, Accessed August 20, 2011.
182. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA (2008) Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: A randomised phase II trial. Lancet Neurol 7, 483-493.
183. Ross JS, Imbimbo BP (2010) Are gamma-secretase inhibitors detrimental for Alzheimer's disease patients? J Alzheimers Dis 22, 401-404.
184. Lalonde R, Dumont M, Fukuchi K, Strazielle C (2002) Transgenic mice expressing the human C99 terminal fragment of betaAPP: Effects on spatial learning, exploration, anxiety, and motor coordination. Exp Gerontol 37, 1401-1412.
185. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, Fahrenholz F (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113, 1456-1464. (Pubitemid 39071701)
186. Panza F, D'Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, Capurso A, Solfrizzi V (2006) Lipid metabolism in cognitive decline and dementia. Brain Res Rev 51, 275-292. (Pubitemid 44183829)
187. Panza F, Solfrizzi V, Colacicco AM, D'Introno A, Capurso C, Palasciano R, Todarello O, Capurso S, Pellicani V, Capurso A (2006) Cerebrovascular disease in the elderly: Lipoprotein metabolism and cognitive decline. Aging Clin Exp Res 18, 144-148. (Pubitemid 43833633)
188. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH (2005) Statin use and the risk of incident dementia: The Cardiovascular Health Study. Arch Neurol 62, 1047-1051. (Pubitemid 41043724)
189. Famer D, Crisby M (2004) Rosuvastatin reduces caspase-3 activity and up-regulates alpha-secretase in human neurob-lastoma SH-SY5Y cells exposed to A beta. Neurosci Lett 371, 209-214. (Pubitemid 39440773)
190. Hoglund K, Thelen KM, Syversen S, Sjogren M, von Bergmann K, Wallin A, Vanmechelen E, Vanderstichele H, Lutjohann D, Blennow K (2005) The effect of simvas-tatin treatment on the amyloid precursor protein and brain cholesterol metabolisminpatients with Alzheimer's disease. Dement Geriatr Cogn Disord 19, 256-265. (Pubitemid 40663319)
191. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci U S A 98, 5815-5820. (Pubitemid 32435725)
192. Parvathy S, Ehrlich M, Pedrini S, Diaz N, Refolo L, Buxbaum JD, Bogush A, Petanceska S, Gandy S (2004) Atorvastatin-induced activation of Alzheimer's alpha sec-retase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. J Neu-rochem 90, 1005-1010. (Pubitemid 39099983)
193. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S (2005) Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2, e18.
194. Gabuzda D, Busciglio J, Yankner BA (1993) Inhibition of beta-amyloid production by activation of protein kinase C. J Neurochem 61, 2326-2329.
195. Garrido JL, Godoy JA, Alvarez A, Bronfman M, Inestrosa NC (2002) Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J 16, 1982-1984.
196. Ibarreta D, Duchen M, Ma D, Qiao L, Kozikowski AP, Etcheberrigaray R (1999) Benzolactam (BL) enhances sAPP secretion in fibroblasts and inPC12 cells. Neuroreport 10, 1035-1040. (Pubitemid 29317986)
197. Kinouchi T, Sorimachi H, Maruyama K, Mizuno K, Ohno S, Ishiura S, Suzuki K (1995) Conventional protein kinase C (PKC)-alpha and novel PKC epsilon, but not -delta, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts. FEBS Lett 364, 203-206.
198. Kozikowski AP, Nowak I, Petukhov PA, Etcheberrigaray R, Mohamed A, Tan M, Lewin N, Hennings H, Pearce LL, Blumberg PM (2003) New amide-bearing benzolactam-based protein kinase C modulators induce enhanced secretion of the amyloid precursor protein metabolite sAPPalpha. J Med Chem 46, 364-373. (Pubitemid 36139789)
199. Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, Greenberg BD, Siman R, Scott RW (1998) Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 18, 1743-1752. (Pubitemid 28103082)
200. Etcheberrigaray R, Tan M, Dewachter I, Kuiperi C, Van der Auwera I, Wera S, Qiao L, Bank B, Nelson TJ, Kozikowski AP, Van Leuven F, Alkon DL (2004) Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc Natl Acad Sci U S A 101, 11141-11146. (Pubitemid 38989597)
201. Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, Wienrich M, Raschig A, Deng M, Growdon JH, Nitsch RM (2000) Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann N Y Acad Sci 920, 285-291. (Pubitemid 32056583)
202. Hock C, Maddalena A, Raschig A, Muller-Spahn F, Eschweiler G, Hager K, Heuser I, Hampel H, Muller-Thomsen T, Oertel W, Wienrich M, Signorell A, Gonzalez-Agosti C, Nitsch RM (2003) Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 10, 1-6. (Pubitemid 36520922)
203. Landhuis E, News: Toulouse: Experimental drug sensitizes receptor, boosts cognition (EVP-6124), http://www. alzforum.org/new/detail.asp?id=2606, November 5, 2010, Accessed April 27, 2011.
204. Drott J, Desire L, Drouin D, Pando M, Haun F (2010) Eta-zolate improves performance in a foraging and homing task in aged rats. Eur J Pharmacol 634, 95-100.
205. Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, Schweighoffer F, Desire L (2008) Etazo-late, a neuroprotective drug linking GABA (A) receptor pharmacology to amyloid precursor protein processing. J Neurochem 106, 392-404. (Pubitemid 351840218)
206. Vellas B, Sol O, Snyder PJ, Ousset PJ, Haddad R, Maurin M, Lemarie JC, Desire L Pando MP (2011) EHT0202 in Alzheimer's Disease: A 3-Month, Randomized, Placebo-Controlled, Double-Blind Study.Curr Alzheimer Res8, 203-212.
207. ExonHit, Therapeutic: Pipeline - EHT 0202, http://www. exonhit.com/therapeutics/pipeline#eht 0202, Accessed August 19, 2011.
208. Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KE, Eckman CB (2006) Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 281, 30471-30478. (Pubitemid 44582103)
209. Eckman EA, Eckman CB (2005) Abeta-degrading enzymes: Modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33, 1101-1105. (Pubitemid 41659123)
210. Kidd PM (2008) Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: Current understanding and progress toward integrative prevention. Altern Med Rev 13, 85-115. (Pubitemid 352009500)
211. Segura J, Ruilope LM (2011) Dual-acting angiotensin receptor-neprilysin inhibition. Curr Hypertens Rep 13, 74-78.
212. Tucker HM, Kihiko M, Caldwell JN, Wright S, Kawarabayashi T, Price D, Walker D, Scheff S, McGillis JP, Rydel RE, Estus S (2000) The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci 20, 3937-3946. (Pubitemid 30365663)
213. Tucker HM, Kihiko-Ehmann M, Wright S, Rydel RE, Estus S (2000) Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. J Neurochem 75, 2172-2177.
214. Van Nostrand WE, Porter M (1999) Plasmin cleavage of the amyloid beta-protein: Alteration of secondary structure and stimulationoftissue plasminogen activator activity.Biochemistry 38, 11570-11576.
215. Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu. J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN (2008) Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 105, 8754-8759. (Pubitemid 351987752)
216. Bu G, Cam J, Zerbinatti C (2006) LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci 1086, 35-53.
217. Cam JA, Bu G (2006) Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol Neurodegene 1, 8.
218. Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, Bu G (2004) The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J Biol Chem 279, 29639-29646. (Pubitemid 38915847)
219. Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, Bu G (2006) Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem 281, 36180-36186. (Pubitemid 46041352)
220. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neu-ropathol 112, 405-415. (Pubitemid 44469161)
221. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, GalaskoD (2011) PF-04494700, anoral inhibitorofreceptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 25, 206-212.
222. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, Lacombe D, Kong X, Aman A, Laurin J, Szarek WA, Tremblay P (2007) Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28, 537-547. (Pubitemid 46282205)
223. Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D (2007) Alzhemed: A potential treatment for Alzheimer's disease. Curr Alzheimer Res 4, 473-478. (Pubitemid 47416642)
224. Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D (2006) A Phase II study targeting amyloid-beta with 3APSinmild-to-moderate Alzheimer disease. Neurology 67, 1757-1763. (Pubitemid 44900749)
225. Saumier D, Aisen PS, Gauthier S, Vellas B, Ferris SH, Duong A, Suhy J, Oh J, Lau W, Garceau D, Haine D, Sampalis J (2009) Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: The ALZHEMED (Tramiprosate) experience. J Nutr Health Aging 13, 370-372.
226. Drugs in Clinical Trials: Alzhemed (Tramiprosate) (Vivi-mind), http://www.alzforum.org/drg/drc/detail.asp?id=84, January 26, 2009, Accessed April 25, 2011.
227. Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, Garceau D, Suhy J, Oh J, Lau W, Sampalis J (2009) Effect of tramiprosate in patients with mild-to- moderate Alzheimer's disease: Exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging 13, 550-557.
228. BellusHealth, About Vivimind. - How does it work? http://www.vivimind. com/about/how-does-it-work/, Accessed July 25, 2011.
229. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lam-bermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St George-Hyslop P (2006) Cyclohexane-hexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12, 801-808. (Pubitemid 44050070)
230. Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJ (2006) Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 60, 668-676. (Pubitemid 46048484)
231. ELAN, Press Release: Elan and Transition. Therapeutics announcetoplinesummary resultsofPhase2studyand plans for Phase3 for ELND005 (Scyllo-inositil), http://newsroom. elan.com/phoenix.zhtml?c=88326&p=irol- newsArticle& ID=1458241, August 9, 2011, Accessed August 20, 2011.
232. ELAN, Drugs in development: ELND005, http://www.elan. com/rd/drugs in development/, Accessed August 20, 2011.
233. Bush AI, Tanzi RE (2002) The galvanization of beta-amyloid in Alzheimer's disease. Proc Natl Acad Sci U S A 99, 7317-7319.
234. Rogers JT, LahiriDK (2004) Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 5, 535-551. (Pubitemid 39004428)
235. Budimir A (2011) Metal ions, Alzheimer's disease and chelation therapy. Acta Pharmaceut 61, 1-14.
236. Bishop GM, Robinson SR (2004) The amyloid paradox: Amyloid-beta-metal complexes can be neurotoxic and neu-roprotective. Brain Pathol 14, 448-452. (Pubitemid 39524973)
237. Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT (2010) Novel drug targets based on metallobiology of Alzheimer's disease. Expert Opin Therap Targets 14, 1177-1197.
238. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, Carey PR (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42, 2768-2773. (Pubitemid 36331519)
239. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158, 47-52. (Pubitemid 28277534)
240. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J (2006) Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid depositsinAlzheimer's disease. J Struct Biol 155, 30-37. (Pubitemid 43867313)
241. Adlard PA, Bush AI (2006) Metals and Alzheimer's disease. J Alzheimers Dis 10, 145-163. (Pubitemid 44763990)
242. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, Andrews DF (1991) Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337, 1304-1308.
243. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 43-55. (Pubitemid 351905863)
244. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676. (Pubitemid 32607332)
245. Lee JY, Friedman JE, Angel I, Kozak A, Koh JY (2004) The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 25, 1315-1321. (Pubitemid 39299169)
246. Moret V, Laras Y, Pietrancosta N, Garino C, Quelever G, Rolland A, Mallet B, Norreel JC, Kraus JL (2006) 1, 1'-Xylyl bis-1, 4, 8, 11-tetraaza cyclotetradecane: A new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution. Bioorg Med Chem Lett 16, 3298-3301.
247. Bareggi SR, Cornelli U (2011) Clioquinol: Review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci Ther, doi: 10.1111/j.1755-5949. 2010.00231.x.
248. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mast-wyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 60, 1685-1691. (Pubitemid 37521621)
249. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786.
250. Morgan D (2011) Immunotherapy for Alzheimer's disease. J Intern Med 269, 54-63.
251. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98, 8850-8855. (Pubitemid 32678116)
252. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5, 452-457. (Pubitemid 34454251)
253. Fu HJ, Liu B, Frost JL, Lemere CA (2010) Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets 9, 197-206.
254. Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Oht-suki S, Terasaki T, Hashimoto T, Iwatsubo T (2009) Abeta immunotherapy: Intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 29, 11393-11398.
255. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 25, 629-636.
256. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33, 67-73.
257. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, Zheng JB, Seabrook TJ, Louard D, Li D, Selkoe DJ, Palmour RM, Ervin FR (2004) Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 165, 283-297. (Pubitemid 38821835)
258. Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Desai R, Hancock WW, Weiner HL, Selkoe DJ (2000) Nasal Abeta treatment induces anti-Abeta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci 920, 328-331. (Pubitemid 32056589)
259. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177. (Pubitemid 29327547)
260. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, Mori C, Issazadeh S, Hancock WW, Selkoe DJ (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48, 567-579.
261. Janus C, Pearson. J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982. (Pubitemid 32101644)
262. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy. J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985. (Pubitemid 32101645)
263. Schenk D (2002) Amyloid-beta immunotherapy for Alzheimer's disease: The end of the beginning. Nat Rev Neurosci 3, 824-828. (Pubitemid 135706694)
264. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64, 94-101. (Pubitemid 40082943)
265. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562. (Pubitemid 40617691)
266. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute menin-goencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61, 46-54. (Pubitemid 36818745)
267. Foster JK, Verdile G, Bates KA, Martins RN (2009) Immunization in Alzheimer's disease: Naive hope or realistic clinical potential? Mol Psychiatry 14, 239-251.
268. Robinson SR, Bishop GM, Lee HG, Munch G (2004) Lessons from the AN 1792 Alzheimer vaccine: Lest we forget. Neurobiol Aging 25, 609-615. (Pubitemid 38686482)
269. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216-223. (Pubitemid 351978111)
270. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 1563-1572. (Pubitemid 40617692)
271. Mann DM, Jones D, South PW, Snowden JS, Neary D (1992) Depositionofamyloid beta proteininnon-Alzheimer dementias: Evidence for a neuronal origin of parenchymal deposits of beta protein in neurodegenerative disease. Acta Neuropathol 83, 415-419.
272. Schmidt W, Reymann KG (2002) Proliferating cells differentiate into neurons in the hippocampal CA1 region of gerbils after global cerebral ischemia. Neurosci Lett 334, 153-156. (Pubitemid 35346847)
273. ACIMMUNE, Clinical Pipeline: ACI-24 (Active Alzheimer's Disease
274. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T (2003) Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 100, 2023-2028. (Pubitemid 36254567)
275. Bard F, Cannon C, Barbour R, Burke RL, Games D, Gra-jeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919. (Pubitemid 30644751)
276. Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM (2005) Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci 25, 6213-6220. (Pubitemid 40923488)
277. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22, 6331-6335. (Pubitemid 35386387)
278. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M (2002) Cerebral hemorrhage after passive anti-Abeta immunotherapy.Scienc 298, 1379. (Pubitemid 35346131)
279. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1, 24.
280. Salloway S, Gur T, Berzin T, Tavares R, Zipser B, Correia S, Hovanesian V, Fallon J, Kuo-Leblanc V, Glass D, Hulette C, Rosenberg C, Vitek M, StopaE (2002) EffectofAPOEgeno-type on microvascular basement membrane in Alzheimer's disease. J Neurol Sci 203-204, 183-187. (Pubitemid 35291188)
281. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos. J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M (2009) Aphase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.
282. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME (2009) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30, 1728-1736.
283. Szabo P, Relkin N, Weksler ME (2008) Natural human antibodies to amyloid beta peptide. Autoimmun Rev 7, 415-420.
284. Bayry J, Kazatchkine MD, Kaveri SV (2007) Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat Clin Pract Neurol 3, 120-121. (Pubitemid 46403934)
285. Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A (2011) Monoclonal antibodies against beta-amyloid (Abeta) for the treatment of Alzheimer's disease: The Abeta target at a crossroads. Expert Opin Biol Ther 11, 679-686.
286. Long JM, Lahiri DK (2011) Current drug targets for modulating alzheimer's amyloid precursor protein: Role of specific micro-RNA species. Curr Med Chem 18, 3314-3321.
287. Patel N, Hoang D, Miller N, Ansaloni S, Huang Q, Rogers JT, Lee JC, Saunders AJ (2008) MicroRNAs can regulate human APP levels. Mol Neurodegener 3, 10.
288. Rodriguez-Lebron E, Gouvion CM, Moore SA, Davidson BL, Paulson HL (2009) Allele-specific RNAi mitigates phe-notypic progression in a transgenic model of Alzheimer's disease. Mol Ther 17, 1563-1573.
289. Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C (2006) Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 65, 1040-1048. (Pubitemid 44684661)
290. Papaioannou N, Tooten PC, van Ederen AM, Bohl JR, Rofina J, Tsangaris T, Gruys E (2001) Immunohistochem-ical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques. Amyloid 8, 11-21. (Pubitemid 32210176)
291. Yu CH, Song GS, Yhee JY, Kim JH, Im KS, Nho WG, Lee JH, Sur JH (2011) Histopathological and immunohis-tochemical comparison of the brain of human patients with Alzheimer's disease and the brain of aged dogs with cognitive dysfunction. J Comp Pathol 145, 45-58.
292. Head E, Pop V, Vasilevko V, Hill M, Saing T, Sarsoza F, Nistor M, Christie LA, Milton S, Glabe C, Barrett E, Cribbs D (2008) A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: Effects on cognitive function and brain Abeta. J Neurosci 28, 3555-3566.
293. Thal DR, Holzer M, Rub U, Waldmann G, Gunzel S, Zedlick D, Schober R (2000) Alzheimer-related tau-pathology in the perforant path target zone and in the hippocampal stratum oriens and radiatum correlates with onset and degree of dementia. Exp Neurol 163, 98-110. (Pubitemid 30314364)
294. Le Corre S, Klafki HW, Plesnila N, Hubinger G, Obermeier A, Sahagun H, Monse B, Seneci P, Lewis. J, Eriksen J, Zehr C, Yue M, McGowan E, Dickson DW, Hutton M, Roder HM (2006) An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A 103, 9673-9678. (Pubitemid 43955883)
295. Schneider A, Mandelkow E (2008) Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 5, 443-457. (Pubitemid 351952490)
296. Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, Williamson R, Fuchs M, Kohler A, Glossmann H, Schneider R, Sutherland C, Schweiger S (2010) Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A 107, 21830-21835.
297. Corcoran NM, Martin D, Hutter-Paier B, Windisch M, Nguyen T, Nheu L, Sundstrom LE, Costello AJ, Hovens CM (2010) Sodium selenate specifically activates PP2A phos-phatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J Clin Neurosci 17, 1025-1033.
298. van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Gotz J, Ittner LM (2010) Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.Proc Natl Acad SciUSA107, 13888-13893.
299. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L (2005) NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11, 353-368.
300. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Water-house EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS (2007) Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31, 165-170. (Pubitemid 46742300)
301. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS (2008) A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive functioninamouse model of Alzheimer's disease. J Pharmacol Exp Ther 325, 146-153. (Pubitemid 351439178)
302. AllonTherapeutics, Allon Therapeutics AL-108 Human Efficacy Data PresentedtoTwo ICAD 2008 Scientific Workshops, http://www.marketwire.com/press- release/Allon-Therapeutics AL-108-Human Efficacy-Data presented-Tw o ICAD-2008 Scientific-Workshops-884162.htm, July 30, 2008, Accessed April 25, 2011.
303. Ashur-Fabian O, Segal-Ruder Y, Skutelsky E, Brenneman DE, Steingart RA, Giladi E, Gozes I (2003) The neu-roprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides 24, 1413-1423. (Pubitemid 38045549)
304. Gozes I, Divinski I (2004) The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J Alzheimers Dis 6, S37-S41. (Pubitemid 40202540)
305. Gozes I, Steingart RA, Spier AD (2004) NAP mechanisms of neuroprotection. J Mol Neurosci 24, 67-72. (Pubitemid 41359169)
306. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM (2006) Inducible expression of Tau repeat domain in cell models of tauopathy: Aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 281, 1205-1214.
307. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 93, 11213-11218. (Pubitemid 26333144)
308. Medina DX, Caccamo A, Oddo S (2011) Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 21, 140-149.
309. Brunden KR, Trojanowski JQ, Lee VM (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8, 783-793.
310. Gura T (2008) Hope in Alzheimer's fight emerges from unexpected places. Nat Med 14, 894.
311. SabbaghMN (2009) Drug development for Alzheimer's disease: Where are we now and where are we headed? Am J Geriatr Pharmacother 7, 167-185.
312. TauRXPharmaceuticals, Alzheimer's disease: TauRx's promising clinical results (Rember (Methylene Blue)), http://www.taurx.com/learn more taurx2.htm, Accessed August 19, 2011.
313. Rafii MS, Aisen PS (2009) Recent developments in Alzheimer's disease therapeutics. BMC Med 7, 7.
314. Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, Kato H, Ames BN (2008) Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 22, 703-712. (Pubitemid 351348123)
315. Congdon EE, Figueroa YH, Wang L, Toneva G, Chang E, Kuret J, Conrad C, Duff KE (2009) Inhibition of tau polymerization withacyanine dyeintwo distinct model systems. J Biol Chem 284, 20830-20839.
316. Chang E, Congdon EE, Honson NS, Duff KE, KuretJ (2009) Structure-activity relationship of cyanine tau aggregation inhibitors. J Med Chem 52, 3539-3547.
317. Bulic B, Pickhardt M, Khlistunova I, Biernat J, Mandelkow EM, Mandelkow E, Waldmann H (2007) Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew Chem Int Ed Engl 46, 9215-9219. (Pubitemid 350292144)
318. Pickhardt M, Biernat J, Khlistunova I, Wang YP, Gazova Z, Mandelkow EM, Mandelkow E (2007) N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. Curr Alzheimer Res 4, 397-402. (Pubitemid 47416632)
319. Pickhardt M, Larbig G, Khlistunova I, Coksezen A, Meyer B, Mandelkow EM, Schmidt B, Mandelkow E (2007) Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46, 10016-10023. (Pubitemid 47378592)
320. Chirita C, Necula M, Kuret J (2004) Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43, 2879-2887. (Pubitemid 38327819)
321. Honson NS, Jensen JR, Darby MV, Kuret J (2007) Potent inhibition of tau fibrillization with a multivalent ligand. Biochem Biophys Res Commun 363, 229-234. (Pubitemid 47430117)
322. Necula M, Chirita CN, Kuret J (2005) Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: Implications for the treatment of tauopathic neurodegener-ative diseases. Biochemistry 44, 10227-10237. (Pubitemid 41076818)
323. Crowe A, Huang W, Ballatore C, Johnson RL, Hogan AM, Huang R, Wichterman. J, McCoy J, Huryn D, Auld DS, Smith AB, 3rd, Inglese J, Trojanowski JQ, Austin CP, Brunden KR, Lee VM (2009) Identification of aminoth-ienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48, 7732-7745.
324. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conform-ers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27, 9115-9129. (Pubitemid 47312068)
325. Sigurdsson EM (2008) Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 15, 157-168.
326. Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M (2006) Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 410, 90-93. (Pubitemid 44709405)
327. Sigurdsson EM (2009) Tau-focused immunotherapy for Alzheimer'sdisease and related tauopathies.CurrAlzheimer Res 6, 446-450.
328. Boutajangout A, Quartermain D, Sigurdsson EM (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30, 16559-16566.
329. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63, 1459-1467. (Pubitemid 44547559)
330. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Nahman NS Jr, Hutton M, Burrows F, Petrucelli L (2007) The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117, 648-658. (Pubitemid 46348523)
331. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H (2003) Chaperones increase association of tau protein with microtubules. Proc Nat Acad Sci U S A 100, 721-726. (Pubitemid 36126119)
332. Koren J, 3rd, Jinwal UK, Lee DC, Jones JR, Shults CL, Johnson AG, Anderson LJ, Dickey CA (2009) Chaperone signalling complexes in Alzheimer's disease. J Cell Mol Med 13, 619-630.
333. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP (1999) The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399, 784-788. (Pubitemid 29293174)
334. Tortosa E, Santa-Maria I, Moreno F, Lim F, Perez M, Avila J (2009) Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J Alzheimers Dis 17, 319-325.
335. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, Burrows F, Eckman C, Hutton M, Petrucelli L (2006) HSP induction mediates selective clearance of tau phos-phorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 20, 753-755. (Pubitemid 46671204)
336. Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Hartl MK, Hartl FU, Wanker EE (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum Mol Genet 10, 1307-1315. (Pubitemid 32600484)
337. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15, 433-442. (Pubitemid 43159895)
338. Klionsky DJ, Emr SD (2000) Autophagy as a regulated pathway of cellular degradation. Science 290, 1717-1721. (Pubitemid 32004796)
339. Ravikumar B, Duden R, Rubinsztein DC (2002) Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 11, 1107-1117. (Pubitemid 34521091)
340. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003) Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278, 25009-25013. (Pubitemid 37548663)
341. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. J Biol Chem 285, 13107-13120.
342. Higgins GC, Beart PM, Shin YS, Chen MJ, Cheung NS, Nagley P (2010) Oxidative stress: Emerging mitochon-drial and cellular themes and variations in neuronal injury. J Alzheimers Dis 20 (Suppl 2), S453-S473.
343. Morais VA, De StrooperB (2010) Mitochondria dysfunction and neurodegenerative disorders: Cause or consequence. J Alzheimers Dis 20 (Suppl 2), S255-S263.
344. Swerdlow RH, Burns JM, Khan SM (2010) The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20 (Suppl 2), S265-S279.
345. Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, Smith MA (2010) Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology 59, 290-294.
346. Perry G, Castellani RJ, Hirai K, Smith MA (1998) Reactive Oxygen Species Mediate Cellular DamageinAlzheimer Disease. J Alzheimers Dis 1, 45-55.
347. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloi-dosis. J Neurosci 21, 4183-4187. (Pubitemid 32538543)
348. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Sied-lak SL, Tabaton M, Perry G (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70, 2212-2215. (Pubitemid 28207848)
349. Zhu X, Raina AK, Perry G, Smith MA (2004) Alzheimer's disease: The two-hit hypothesis. Lancet Neurol 3, 219-226. (Pubitemid 38373660)
350. Scheltens P (2009) Moving forward with nutrition in Alzheimer's disease. Eur J Neurol 16 (Suppl 1), 19-22.
351. Kim J, Lee HJ, Lee KW (2010) Naturally occurring phy-tochemicals for the prevention of Alzheimer's disease. J Neurochem 112, 1415-1430.
352. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287, 3223-3229. (Pubitemid 34686103)
353. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Wilson RS, Scherr PA (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimerdiseaseinabiracial community study.JAMA 287, 3230-3237. (Pubitemid 34686104)
354. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS (2002) Vitamin E and cognitive decline in older persons. Arch Neurol 59, 1125-1132. (Pubitemid 34755825)
355. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS, Aggarwal NT, Scherr PA (2005) Relation of the tocopherol formstoincidentAlzheimerdisease andtocognitive change. Am J Clin Nutr 81, 508-514. (Pubitemid 43073356)
356. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New Engl J Med 336, 1216-1222. (Pubitemid 27183651)
357. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol 61, 82-88. (Pubitemid 38067418)
358. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial. Arch Neurol 63, 1402-1408. (Pubitemid 44547551)
359. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS (2005) Fish consumption and cognitive decline with age in a large community study. Arch Neurol 62, 1849-1853. (Pubitemid 41785078)
360. Scarmeas N, Luchsinger JA, Mayeux R, Stern Y (2007) Mediterranean diet and Alzheimer disease mortality. Neurology 69, 1084-1093. (Pubitemid 47517553)
361. Solfrizzi V, Colacicco AM, D'Introno A, Capurso C, Del Parigi A, Capurso SA, Argentieri G, Capurso A, Panza F (2006) Dietary fatty acids intakes and rate of mild cognitive impairment. The Italian Longitudinal Study on Aging. Exp Gerontol 41, 619-627. (Pubitemid 43867225)
362. Solfrizzi V, Colacicco AM, D'Introno A, Capurso C, Torres F, Rizzo C, Capurso A, Panza F (2006) Dietary intake of unsaturated fatty acids and age-related cognitive decline: A 8.5-year follow-up of the Italian Longitudinal Study on Aging. Neurobiol Aging 27, 1694-1704. (Pubitemid 44363108)
363. Birks J, Grimley Evans J (2009) Ginkgo biloba for cognitive impairment and dementia.Cochrane Database Syst Rev, CD003120.
364. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD (2008) Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA 300, 2253-2262.
365. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial. Arch Neurol 63, 1402-1408. (Pubitemid 44547551)
366. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 54, 111-118.
367. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF (1997) A placebo-controlled, doubleblind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 278, 1327-1332. (Pubitemid 27449692)
368. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N Jr, Frautschy SA, Cole GM (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neu-rosci 25, 3032-3040. (Pubitemid 40463537)
369. Lloret A, Badia MC, Mora NJ, Pallardo FV, Alonso MD, Vina J (2009) Vitamin E paradox in Alzheimer's disease: It does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis 17, 143-149.
370. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye. J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. New Engl J Med 352, 2379-2388. (Pubitemid 40958434)
371. Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M (2005) A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2, 541-551. (Pubitemid 41703672)
372. Sun Y, Lu CJ, Chien KL, Chen ST, Chen RC (2007) Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: A 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin Ther 29, 2204-2214. (Pubitemid 350138567)
373. van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Dullemeijer C, Olderikkert MG, Beekman AT, de Groot CP (2008) Effect of fish oil on cognitive performance in older subjects: A randomized, controlled trial. Neurology 71, 430-438.
374. van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG (2000) The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: New results of a randomized clinical trial. J Am Geriatr Soc 48, 1183-1194.
375. Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, Irizarry MC (2009) Plasma Abeta, homocysteine, and cognition: The Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology 72, 268-272.
376. Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, Thiyagarajan M, Percival SS, Talcott ST, Pasinetti GM (2006) Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J 20, 2313-2320. (Pubitemid 44953861)
377. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol 61, 82-88. (Pubitemid 38067418)
378. Aliev G, Liu. J, Shenk JC, Fischbach K, Pacheco GJ, Chen SG, Obrenovich ME, Ward WF, Richardson AG, Smith MA, Gasimov E, Perry G, Ames BN (2009) Neuronal mitochon-drial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J Cell Mol Med 13, 320-333.
379. Ji HF, Zhang HY (2008) Multipotent natural agents to combat Alzheimer's disease. Functional spectrum and structural features. Acta Pharmacol Sin 29, 143-151.
380. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, Ames BN (2002) Memory lossin old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: Partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci U S A 99, 2356-2361. (Pubitemid 34169065)
381. Long J, Gao F, Tong L, Cotman CW, Ames BN, Liu J (2009) Mitochondrial decay in the brains of old rats: Ame liorating effect of alpha-lipoic acid and acetyl-L-carnitine. Neurochem Res 34, 755-763.
382. Singh M, Arseneault M, Sanderson T, Murthy V, Ramas-samyC (2008) Challenges for researchonpolyphenols from foods in Alzheimer's disease: Bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem 56, 4855-4873. (Pubitemid 352039080)
383. McGeer PL, McGeer EG (2007) NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging 28, 639-647. (Pubitemid 46349357)
384. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol l9, 1118-1127.
385. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, ScheltensP (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
386. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B (2011) Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76, 280-286.
387. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grund-man M, Thal LJ (2000) A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54, 588-593. (Pubitemid 30082922)
388. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 289, 2819-2826. (Pubitemid 37430117)
389. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC (1994) Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 44, 227-232. (Pubitemid 24070956)
390. Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M (2007) Naproxen and celecoxib do not preventADinearly results fromarandomized controlled trial. Neurology 68, 1800-1808. (Pubitemid 46791392)
391. Meinert CL, McCaffrey LD, BreitnerJC (2009) Alzheimer's Disease Anti-inflammatory Prevention Trial: Design, methods, and baseline results. Alzheimers Dement 5, 93-104.
392. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC (2004) Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62, 66-71. (Pubitemid 38082872)
393. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P et al (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43, 1609-1611. (Pubitemid 23230557)
394. Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632. (Pubitemid 27120096)
395. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA (2005) A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychophar- macology 30, 1204-1215. (Pubitemid 40720980)
396. Van Gool WA, Weinstein HC, Scheltens P, WalstraGJ (2001) Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: An 18-month randomised, double-blind, placebo-controlled study. Lancet 358, 455-460. (Pubitemid 32769852)
397. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjo-hann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T (2001) Sim-vastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42and Abeta 40in vitroandin vivo. Proc Natl Acad Sci U S A 98, 5856-5861. (Pubitemid 32435732)
398. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
399. Kuller LH (2007) Statins and dementia. Curr Atheroscler Rep 9, 154-161. (Pubitemid 47376986)
400. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360, 1623-1630. (Pubitemid 35379733)
401. Sjogren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, Wallin A, Blennow K (2003) Treatment with simvastatin inpatients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 16, 25-30. (Pubitemid 36469809)
402. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P (2006) Circulating cholesterol levels, apolipopro-tein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: Results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 185, 3-7. (Pubitemid 44015218)
403. Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, Johnson-Traver S, Ziolkowski C, Browne P (2006) Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 185, 78-86. (Pubitemid 44015229)
404. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziol-wolski C (2005) Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Arch Neu-rol 62, 753-757. (Pubitemid 40656090)
405. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Petanceska S, Browne P, Wassar D, Johnson-Traver S, Lochhead J, Ziolkowski C (2005) Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Curr Alzheimer Rese 2, 343-353. (Pubitemid 40980193)
406. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57, 1439-1443.
407. Zhou B, Teramukai S, Fukushima M (2007) Prevention and treatment of dementia or Alzheimer's disease by statins: A meta-analysis. Dement Geriatr Cogn Disord 23, 194-201. (Pubitemid 46333787)
408. Heneka MT, Landreth GE (2007) PPARs in the brain. Biochim Biophys Acta 1771, 1031-1045. (Pubitemid 47208548)
409. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's dis-ease:Arandomised, double-blind, placebo-controlled study. Lancet 372, 207-215. (Pubitemid 351978110)
410. Medivation, Pfizer and Medivation announce results from two phase 3 studies in dimebon (latrepiridine) Alzheimer's Disease Clinical Development Program, http://investors.medivation.com/releasedetail.cfm? Relea-seID=448818, Accessed August 20, 2011.
411. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, Dennis MS (2011) Boosting brain uptakeofatherapeutic antibodybyreducing its affinity for a transcytosis target. Science Transl Med 3, 84ra44.
412. Jessberger S, Kempermann G (2003) Adult-born hippocam-pal neurons mature into activity-dependent responsiveness. Eur J Neurosci 18, 2707-2712. (Pubitemid 37542123)
413. Ramirez-Amaya V, Marrone DF, Gage FH, Worley PF, BarnesCA (2006) Integrationofnew neurons intofunctional neural networks. J Neurosci 26, 12237-12241. (Pubitemid 44808390)
414. Trouche S, Bontempi B, Roullet P, Rampon C (2009) Recruitment of adult-generated neurons into functional hippocampal networks contributes to updating and strengthening of spatial memory. Proc Natl Acad Sci U S A 106, 5919-5924.
415. Nakatomi H, Kuriu T, Okabe S, Yamamoto S, Hatano O, Kawahara N, Tamura A, Kirino T, Nakafuku M (2002) Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell 110, 429-441. (Pubitemid 35232287)
416. Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA (2004) Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci U S A 101, 343-347. (Pubitemid 38084252)
417. Rodriguez JJ, Jones VC, Tabuchi M, Allan SM, Knight EM, LaFerla FM, Oddo S, Verkhratsky A (2008) Impaired adult neurogenesis in the dentate gyrus of a triple trans-genic mouse model of Alzheimer's disease. PloS One 3, e2935.
418. Varela-Nallar L, Aranguiz FC, Abbott AC, Slater PG, Ine-strosa NC (2010) Adult hippocampal neurogenesis in aging and Alzheimer's disease. Birth Defects Res C Embryo Today 90, 284-296.
419. Waldau B, Shetty AK (2008) Behavior of neural stem cells in the Alzheimer brain. Cell Mol Life Sci 65, 2372-2384.
420. Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerlaFM (2009) Neural stemcells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 106, 13594-13599.
421. Li Z, Gao C, Huang H, Sun W, Yi H, Fan X, Xu H (2010) Neurotransmitter phenotype differentiation and synapse formation of neural precursors engrafting in amyloid-beta injured rat hippocampus. J Alzheimers Dis 21, 1233-1247.
422. Laboratory DH, Tau phosphorylation sites, http://cnr.iop. kcl.ac.uk/hangerlab/tautable/, Accessed April 29, 2011.